Premium
Cardiorespiratory function in stable methadone maintenance treatment (MMT) patients
Author(s) -
Teichtahl Harry,
Wang David,
Cunnington David,
Kronborg Ian,
Goodman Cathy,
Prodromidis Andy,
Drummer Olaf
Publication year - 2004
Publication title -
addiction biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.445
H-Index - 78
eISSN - 1369-1600
pISSN - 1355-6215
DOI - 10.1111/j.1369-1600.2004.tb00540.x
Subject(s) - cardiorespiratory fitness , methadone maintenance , methadone , medicine , psychology , psychiatry , physical therapy
Patients in methadone maintenance programmes (MMT) often smoke tobacco and cannabis and many have ongoing illicit drug use. There is therefore potential for these patients to have abnormal cardiorespiratory function; however, few studies address this in stable MMT patients. We assessed resting cardiorespiratory function on 50 stable MMT patients (25 males, 25 females). Forty‐six MMT patients were current tobacco smokers, 19 were current cannabis users and none were currently using opioids other than prescribed methadone. We defined abnormalities of respiratory function as those results outside the 95% confidence interval of reference values for normal subjects adjusted for age, weight, height and sex. Thirty‐one (62%) MMT patients had reduced carbon monoxide transfer factor (D L CO); 17 (34%) had elevated single breath alveolar volume (V A) and 43 (86%) had a reduced D L CO/V A ratio. Six patients (12%) had reduced FEV 1; one (2%) had reduced FVC; and nine (18%) had an obstructive ventilatory defect. Ten (20%) patients had PaCO 2 higher than 45 mmHg and 14 (28%) had alveolar to arterial oxygen gradient (A‐aPO 2) higher than 15 mmHg. CXR, Echocardiography and ECG showed no significant abnormalities. We conclude that stable MMT patients have abnormalities of resting respiratory function which may be due to ongoing tobacco cigarette and current or past cannabis smoking.